Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Genentech
< Previous
1
2
3
Next >
Genentech to Present Data at ASH 2022 Showcasing Strength of Hematology Portfolio and Expanding Into New Areas to Address More Patient Needs
November 03, 2022
From
Genentech
Via
Business Wire
Tickers
RHHBY
Positive Topline Phase III Results Show Genentech’s Vabysmo Improved Vision for People Living With Retinal Vein Occlusion (RVO)
October 27, 2022
From
Genentech
Via
Business Wire
Tickers
RHHBY
Early Treatment With Genentech’s Ocrevus (ocrelizumab) Leads to Reduced Disease Progression and Healthcare Costs; Nine-Year Safety Data Reinforce Favorable Benefit-Risk Profile
October 26, 2022
From
Genentech
Via
Business Wire
Tickers
RHHBY
Genentech to Present New Ocrevus (ocrelizumab) Data in Multiple Sclerosis and Continued Research Into Neuromyelitis Optica Spectrum Disorder at ECTRIMS 2022
October 19, 2022
From
Genentech
Via
Business Wire
Tickers
RHHBY
Positive New Data for Genentech’s Evrysdi in Largest Trial Ever Undertaken in Patients With Previously-Treated Spinal Muscular Atrophy (SMA)
October 12, 2022
From
Genentech
Via
Business Wire
Tickers
RHHBY
FDA Accepts Supplemental Biologics License Application for Genentech's Polivy Combination for People With Previously Untreated Diffuse Large B-Cell Lymphoma
August 16, 2022
From
Genentech
Via
Business Wire
Tickers
RHHBY
Genentech Announces FDA Approval of Xofluza to Treat Influenza in Children Aged Five and Older
August 11, 2022
From
Genentech
Via
Business Wire
Tickers
RHHBY
Genentech’s Subcutaneous Formulation of Tecentriq Demonstrates Positive Phase III Results
August 02, 2022
From
Genentech
Via
Business Wire
Tickers
RHHBY
Genentech to Present Scientific Progress Across Alzheimer’s Disease Pharmaceutical and Diagnostic Portfolio at 2022 AAIC Annual Meeting
July 28, 2022
From
Genentech
Via
Business Wire
Tickers
RHHBY
New Two-Year Data Confirm Genentech’s Vabysmo Improves Vision With Fewer Treatments for People With Wet Age-Related Macular Degeneration
July 14, 2022
From
Genentech
Via
Business Wire
Tickers
RHHBY
New Data From Phase III HAVEN 6 Study Reinforce Favorable Safety and Efficacy Profile of Genentech’s Hemlibra (emicizumab-kxwh) in People With Moderate or Mild Hemophilia A
July 11, 2022
From
Genentech
Via
Business Wire
Tickers
RHHBY
FDA Grants Priority Review to Genentech’s Mosunetuzumab for People With Relapsed or Refractory Follicular Lymphoma
July 06, 2022
From
Genentech
Via
Business Wire
Tickers
RHHBY
Genentech Provides Update on Alzheimer’s Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease
June 16, 2022
From
Genentech
Via
Business Wire
Tickers
RHHBY
Genentech Announces Positive Data from Broad Blood Cancer Portfolio at European Hematology Association Annual Meeting
June 10, 2022
From
Genentech
Via
Business Wire
Tickers
RHHBY
FDA Approves Genentech’s Evrysdi (risdiplam) for Use in Babies Under Two Months With Spinal Muscular Atrophy (SMA)
May 31, 2022
From
Genentech
Via
Business Wire
Tickers
RHHBY
New Pivotal Data Demonstrate Clinical Benefit of Genentech’s Glofitamab, a Potential First-in-Class Bispecific Antibody for People With Aggressive Lymphoma
May 26, 2022
From
Genentech
Via
Business Wire
Tickers
RHHBY
Data at the 2022 ASCO Annual Meeting Highlight Genentech’s Continued Commitment to Innovation in Oncology and Personalized Healthcare
May 24, 2022
From
Genentech
Via
Business Wire
Tickers
RHHBY
Genentech Reports Interim Results for Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer
May 11, 2022
From
Genentech
Via
Business Wire
Tickers
RHHBY
New Three-Year Data for Genentech’s Evrysdi (risdiplam) Show Long-Term Improvements in Survival and Motor Milestones in Babies With Type 1 Spinal Muscular Atrophy (SMA)
April 29, 2022
From
Genentech
Via
Business Wire
Tickers
RHHBY
New Data for Genentech’s Ocrevus (ocrelizumab) Show Benefit in Disability Progression and Cognitive Decline in Both Secondary Progressive and Primary Progressive Multiple Sclerosis
April 04, 2022
From
Genentech
Via
Business Wire
Tickers
RHHBY
U.S. FDA Grants Priority Review to Genentech’s Actemra for the Treatment of COVID-19 in Hospitalized Adults
April 04, 2022
From
Genentech
Via
Business Wire
Tickers
RHHBY
Genentech Provides Update on Phase III SKYSCRAPER-02 Study in Extensive-Stage Small Cell Lung Cancer
March 30, 2022
From
Genentech
Via
Business Wire
Tickers
RHHBY
Genentech to Present Data Across Broad and Impactful Neuroscience Portfolio at 2022 AAN Annual Meeting
March 25, 2022
From
Genentech
Via
Business Wire
Tickers
OTC
New Data for Genentech’s Evrysdi (risdiplam) Demonstrate Long-Term Efficacy and Safety in a Broad Population of People With Spinal Muscular Atrophy (SMA)
March 16, 2022
From
Genentech
Via
Business Wire
Tickers
RHHBY
New Two-Year Data for Genentech’s Vabysmo and Susvimo Reinforce Potential to Maintain Vision With Fewer Treatments for People With Two Leading Causes of Vision Loss
February 11, 2022
From
Genentech
Via
Business Wire
Tickers
RHHBY
FDA Approves Genentech’s Vabysmo, the First Bispecific Antibody for the Eye, to Treat Two Leading Causes of Vision Loss
January 28, 2022
From
Genentech
Via
Business Wire
Tickers
RHHBY
Genentech’s Evrysdi (risdiplam) Granted FDA Priority Review for Treatment of Pre-Symptomatic Babies Under 2 Months of Age With Spinal Muscular Atrophy (SMA)
January 25, 2022
From
Genentech
Via
Business Wire
Tickers
RHHBY
The Lancet Publishes Studies Showing Genentech’s Faricimab Improved and Maintained Vision in Two Leading Causes of Vision Loss, Extending Time Between Treatments up to Four Months
January 24, 2022
From
Genentech
Via
Business Wire
Tickers
RHHBY
Genentech’s Polivy Combination Reduced the Risk of Disease Worsening or Death by 27% in People With Previously Untreated Aggressive Form of Lymphoma
December 14, 2021
From
Genentech
Via
Business Wire
Tickers
RHHBY
Interim Data From Phase III HAVEN 6 Study Demonstrate Favorable Safety and Efficacy Profile of Genentech’s Hemlibra (emicizumab-kxwh) in People With Moderate or Mild Hemophilia A
December 13, 2021
From
Genentech
Via
Business Wire
Tickers
RHHBY
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.